Circulating interleukin-15 in dementia disorders

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 19, Issue 3, 2007, Pages 318-325

  Rentzos, Michael ^a   Paraskevas, George P ^a   Kapaki, Elisabeth ^a   Nikolaou, Chryssoula ^a   Zoga, Margarita ^a   Tsoutsou, Anthousa ^a   Rombos, Antonis ^a   Vassilopoulos, Demetrios ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; INTERLEUKIN 15;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE DURATION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOASSAY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; SEX; TREATMENT DURATION;

EID: 34548069376     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2007.19.3.318     Document Type: Article

References (62)

1. Doherty TM, Seder RA, Sher A: Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996; 156:735-741
2. Jonuleit H, Wiedemann K, Muller G, et al: Induction of IL-15 messenger RNA and protein in human blood-derived dendritic cells. J Immunol 1997; 160:2610-2615
3. Lee YB, Satoh J, Walker DG, et al: Interleukin-15 gene expression in human astrocytes and microglia in culture. Neuroreport 1996; 7:1062-1066
4. Carson WE, Giri JG, Lindemann MJ, et al: IL-15 is a novel cytokine that activates human NK cells via components of IL-2 receptor. J Exp Med 1994; 180:1395-1405
5. Grabstein KH, Eisenmann J, Shanebeck K, et al: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965-968
6. Uchikado H, Akiyama H, Kondo H, et al: Activation of vascular endothelial cells and perivascular cells by systemic inflammation - an immunohistochemical study of postmortem human brain tissues. Acta Neuropathol 2004; 107:341-351
7. Eikelenboom P, Hoogendijk WJG, Jonker C, et al: Immunological mechanisms and the spectrum of psychiatric syndromes in Alzheimer 's disease. J Psychiatr Res 2002; 36:269-280
8. Blalock JE: The syntax of immune-neuroendocrine communication. Immunol Today 1994; 15:504-511
9. Gambi F, Reale M, Iarlori C, et al: Alzheimer's patients treated with an ACHE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol 2004; 24:314-321
10. Verbeek MM, Otte-Holler I, Westphal JR, et al: Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 1991; 144:104-116
11. Hussain L, Powell D, Howlett D et al: Identification of a novel aspartic protease (Asp2) as [beta]-secretase. Mol Cell Neurosci 1999; 14:419-427
12. Akiyama H, Arai T, Kondo H, et al: Cell mediators of inflammation in the Alzheimer's disease brain. Alzheimer Dis Assoc Disord 2000; 14(suppl):S47-S53
13. McGeer PL, Kawamata T, Walker DG, et al: Microglia in degenerative neurological disease. Glia 1993; 7:84-92
14. Yong BL, Atsushi N, Seung UK: Cytokines, chemokines and cytokine receptors in human microglia. J Neurosci Res 2002; 69:94-103
15. Schnabel J: New Alzheimer's therapy suggested. Science 1993; 260:1719-1720
16. Shoji M, Hirai S, Yamaguchi H, et al: Alpha 1-antichymotrypsin is present in diffuse senile plaques. Am J Pathol 1991; 138:247-257
17. Strauss S, Bauer J, Ganter U, et al: Detection of interleukin-6 and α-2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992; 66:223-230
18. Vandenabeele P, Fiers W: Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated "acute phase response" in the brain? Immunol Today 1991; 12:217-219
19. Rentzos M, Michalopoulou M, Nikolaou C, et al: The role of soluble intercellular adhesion molecules in neurodegenerative disorders. J Neurol Sci 2005; 228:129-135
20. Chao CC, Hu S, Ehrlich L, et al: Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun 1995; 9:355-365
21. Hachinski V, Munoz DG: Cerebrovascular pathology in Alzheimer's disease: cause, effect or epiphenomenon? Ann N Y Acad Sci 1997; 826:1-6
22. Carmelli D, Swan GF, Reed T, et al: Midlife cardiovascular risk factors, APOE, and cognitive decline in elderly male twins. Neurology 1998; 50:1580-1585
23. Haan MN, Shemanski I, Jagust WJ, et al: The role of APOE ε4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999; 282:40-46
24. Jagust W: Untangling vascular dementia. Lancet 2001; 358:2097-2098
25. Inestrosa NC, Alvarez A, Perez CA, et al: Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16:881-891
26. Mesulam MM: Alzheimer's plaques and cortical cholinergic innervation. Neuroscience 1986; 17:275-276
27. Feldman H, Gauuthier S, Hecker J for the Donepezil Study Group: Benefits of donepezil on global function, behaviour, cognition, and ADLs in patients with moderate-to-severe Alzheimer's disease. Neurology 2000; 54(suppl 13):A469
28. Mohs R, Doody RS, Morris J: A1-year placebo-controlled preservation of function survival study of donepezil in Alzheimer's disease patients. Neurology 2001; 5:481-488
29. Lugaresi A, Di Iorio A, Iarlori C, et al: IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors. Exp Gerontol 2004; 39:653-657
30. Reale M, Iarlori C, Gambi F, et al: Treatment with an acetylcholinesterase inhibitor in Alzheimer's patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol 2004; 148:162-171
31. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984; 34:939-944
32. Hachinski VC, Iliff LD, Zilh E, et al: Cerebral blood flow in dementia. Arch Neurol 1975; 32:632-637
33. Roman GC, Tatemichi TK, Erkinjunti T, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN international workshop. Neurology 1993; 43:250-260
34. Sala G, Galimberti G, Carnevari C, et al: Peripheral cytokine release in Alzheimer patients: correlation with disease severity. Neurobiol Aging 2003; 24:909-914
35. De Luigi A, Fragiacomo C, Lucca U, et al: Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 2001; 122:1985-1995
36. Lombardi VR, Garcia M, Rey L, Cacabelos R: Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (Alzheimer's disease) individuals. J Neuroimmunol 1999; 97:163-171
37. Singh V, Guthikonda P: Circulating cytokines in Alzheimer's disease. J Psych Res 1997; 31:657-660
38. De Luigi A, Pizzimenti S, Quadri P, et al: Peripheral inflammatory response in Alzheimer's disease and multiinfarct dementia. Neurobiol Dis 2002; 11:308-314
39. Monsonego A, Maron R, Zota V, et al: Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. PNAS 2001; 98:10273-10278
40. Hatzinger M, Z'Brun A, Hemmeter U, et al: Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol Aging 1995; 16:205-209
41. Wiegers GJ, Reul JM: Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci 1998; 19:317-321
42. Szczepanic AM, Rampe D, Ringheim GE: Amyloid-beta peptide fragment p3 and p4 induce pro-inflammatory cytokine and chemokine production in vitro and in vivo. J Neurochem 2001b; 77:304-317
43. Yates SI, Burgess LH, Kocsis-Angle J, et al: Amyloid beta and myelin fibers include increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia. J Neurochem 2000; 74:1017-1025
44. De Luigi A, Terreni I, Sironi M, et al: The sympathetic nervous system tonically inhibit peripheral interleukin-1β and interleukin-6 induction by central lipopolysaccharide. Neuroscience 1998; 83:1245-1250
45. De Simoni MG, Del Bo R, De Luigi A, et al: Central endotoxin induces different patterns of interleukin-1beta and IL-6 messenger ribonucleic acid expression and IL-6 secretion in the brain and periphery. Endocrinology 1995; 136:897-902
46. De Simoni MG, Sironi M, De Luigi A, et al: Intracerebroventricular injection of interleukin-1 induces high circulating levels of interleukin-6. J Exp Med 1990; 171:1773-1778
47. Chamorro A: Role of inflammation in stroke and atherothrombosis. Cerebrovasc Dis 2004; 17(suppl 3):1-5
48. Castillo J, Rodriguez I: Biochemical changes and inflammatory response as markers brain ischemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004; 17(suppl 1):7-18
49. Lynch JR, Blessing R, White WD, et al: Novel diagnostic test for acute stroke. Stroke 2004; 35:57-68
50. Bartosik-Psujek H, Belniak E, Stelmasiak Z: Markers of inflammation in cerebral ischemia. Neurol Sci 2003; 24:279-280
51. Jia JP, Meng R, Sun YX, et al: Cerebrospinal fluid tau, Aβ1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett 2005; 383:12-16
52. Stys PK, Jiang Q: Calpain-dependent neurofilament breakdown in anoxic and ischemic rat central axons. Neurosci Lett 2002; 328:150-154
53. Cacabelos R, Alvarez XA, Franco-Maside A, et al: Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1994; 16:29-35
54. Paganelli R, Di Iorio A, Patricelli L, et al: Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp Gerontol 2002; 37:257-263
55. Inestrosa NC, Alarcon R, Arriagada J, et al: Blood markers in Alzheimer's disease: subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. J Neurol Sci 1994; 122:1-5
56. Kawashima K, Fujii T: The lymphocytic cholinergic system and its biological function. Life Sci 2003; 72:2101-2109
57. Kawashima K, Fujii T: Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86:29-48
58. Kawashima K, Fujii T, Watanabe Y, et al: Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytes. Life Sci 1998; 62:1701-1705
59. Chao CC, Molitor TW, Hu S: Neuroprotective role of IL-4 against activated microglia. J Immunol 1993; 151:1473-1481
60. Tayebati SK, Amenta F, Amici S, et al: Peripheral blood lymphocytes muscarinic cholinergic receptor subtypes in Alzheimer's disease: a marker of cholinergic dysfunction? J Neuroimmunol 2001; 121:126-131
61. Cotman CW: The role of neurotrophins in brain aging: a perspective in honor of Regino Perez-Polo. Neurochem Res 2005; 30:877-881
62. Rentzos M, Zoga M, Paraskevas GP, et al: IL-15 is elevated in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J Geriatr Psychiatry Neurol 2006; 19:114-117